/ Pharmacology reference
Peptide half-life, side by side.
Half-life is the time it takes for a compound to fall to half its concentration in the body. It ranges from a couple of minutes for some peptides to about a week for the long-acting GLP-1 compounds. The table covers every compound in the library. Sort it by name, category, or half-life, and filter by class. Educational reference only, not medical advice, a schedule, or a dosing recommendation.
94 compounds · sorted by half-life (ascending)
| Reference | |||
|---|---|---|---|
| ARA-290Cibinetide | Healing / Recovery | Short; ~2 min (IV), ~10-20 min terminal (subcutaneous) | Verified |
| KisspeptinKisspeptin-10 · Kisspeptin-54 | Sexual / Hormonal | Kisspeptin-10 ~4 min; kisspeptin-54 ~27.6 min, intravenous | Verified |
| Semax | Cognitive / Longevity | Minutes in plasma (~2-5 min); intranasal or subcutaneous | Verified |
| OxytocinPitocin | Sexual / Hormonal | ~1 to 6 min in plasma | Verified |
| GonadorelinGnRH · Factrel | Sexual / Hormonal | ~2-10 min (IV distribution); terminal ~10-40 min | Verified |
| BPC-157Body Protection Compound · PL 14736 | Healing / Recovery | Short; ~15 min (rat, IV); no human PK published | Verified |
| DSIPDelta Sleep-Inducing Peptide | Cognitive / Longevity | Short, minutes in plasma (~7-15 min reported); IV or subcutaneous | Verified |
| GlucagonGlucaGen | GLP-1 / Metabolic | ~8-18 min, injection | Verified |
| SermorelinGeref · GHRH 1-29 | Growth Hormone | ~10-20 min (reported ~12 min), subcutaneous | Verified |
| GHRP-2Pralmorelin | Growth Hormone | Short; ~30 min (approximate), subcutaneous | Verified |
| GHRP-6 | Growth Hormone | Short; ~20-30 min (some studies report up to ~2.5 h), subcutaneous | Verified |
| TesamorelinEgrifta | GLP-1 / Metabolic | ~26-38 min, subcutaneous | Verified |
| MOTS-cMOTSc | GLP-1 / Metabolic | Not well characterized in humans; preclinical estimates short (~45 min to a few hours) | Verified |
| PramlintideSymlin · SymlinPen | GLP-1 / Metabolic | ~48 min, subcutaneous | Verified |
| Hexarelin | Growth Hormone | ~55 min (human, subcutaneous); ~76 min IV in animal studies | Verified |
| Calcitonin SalmonMiacalcin · Fortical | Healing / Recovery | ~58 min intramuscular, ~59-64 min subcutaneous | Verified |
| AbaloparatideTymlos · BA058 | Healing / Recovery | ~1 h, subcutaneous | Verified |
| AOD-9604AOD9604 · hGH 176-191 | GLP-1 / Metabolic | Not well characterized in humans; reported short (minutes to ~1 h) | Verified |
| Melanotan IIMT-2 · MT2 | Sexual / Hormonal | ~1 h, subcutaneous (limited human PK) | Verified |
| OctreotideSandostatin · Octreotide acetate | Growth Hormone | ~1.7-1.9 h, injection | Verified |
| Ipamorelin | Growth Hormone | ~2 h, subcutaneous | Verified |
| SS-31Elamipretide | Cognitive / Longevity | ~2 h, subcutaneous or IV | Verified |
| TeduglutideGattex · Revestive | Healing / Recovery | ~2 h in healthy subjects, ~1.3 h in short bowel syndrome, subcutaneous | Verified |
| ExenatideByetta · Bydureon | GLP-1 / Metabolic | ~2.4 h (terminal), subcutaneous | Verified |
| DesmopressinDDAVP · Desmopressin acetate | Healing / Recovery | ~1.5-2.5 h, oral | Verified |
| PT-141Bremelanotide · Vyleesi | Sexual / Hormonal | ~2.7 h terminal (range 1.9-4.0 h), subcutaneous | Verified |
| Thymosin Alpha-1Tα1 · Zadaxin | Healing / Recovery | ~2-3 h, subcutaneous | Verified |
| 5-Amino-1MQ5A1MQ | Cognitive / Longevity | ~3.8 h IV and ~6.9 h oral in rat; no published human PK | Verified |
| NAD+Nicotinamide adenine dinucleotide | Cognitive / Longevity | Intracellular turnover ~1-4 h (compartment-dependent); a single plasma half-life is not well defined | Verified |
| MacimorelinMacrilen · AEZS-130 | Growth Hormone | ~4.1 h terminal, oral | Verified |
| SetmelanotideImcivree · RM-493 | GLP-1 / Metabolic | ~11 h, subcutaneous | Verified |
| LiraglutideSaxenda · Victoza | GLP-1 / Metabolic | ~13 h, subcutaneous | Verified |
| AfamelanotideScenesse · Melanotan-1 | Sexual / Hormonal | ~15 h, controlled-release subcutaneous implant | Verified |
| MK-677Ibutamoren · Nutrobal | Growth Hormone | ~24 h, oral | Verified |
| Pentosan PolysulfatePPS · Elmiron | Healing / Recovery | ~20-27 h (plasma radioactivity), oral | Verified |
| IGF-1 LR3Long R3 IGF-1 | Cognitive / Longevity | ~20-30 h reported (subcutaneous); some sources cite longer | Verified |
| HCGHuman Chorionic Gonadotropin · Novarel | Sexual / Hormonal | Biphasic; terminal ~24-36 h, intramuscular or subcutaneous | Verified |
| OrforglipronFOUNDAYO · LY3502970 | GLP-1 / Metabolic | ~29-49 h, oral | Verified |
| DulaglutideTrulicity | GLP-1 / Metabolic | ~5 days, subcutaneous | Verified |
| TirzepatideMounjaro · Zepbound | GLP-1 / Metabolic | ~5 days (~120 h), subcutaneous | Verified |
| PegvisomantSomavert · B2036-PEG | Growth Hormone | ~60-138 h, subcutaneous | Verified |
| RetatrutideReta · Triple-G | GLP-1 / Metabolic | ~6 days, subcutaneous | Verified |
| CagrilintideCagri · NN9838 | GLP-1 / Metabolic | ~7 days (~6-8 days), subcutaneous | Verified |
| SemaglutideOzempic · Wegovy | GLP-1 / Metabolic | ~1 week (~168 h), subcutaneous | Verified |
| SurvodutideBI 456906 | GLP-1 / Metabolic | ~6-7 days, subcutaneous | Verified |
| CJC-1295with DAC · mod GRF 1-29 | Growth Hormone | With DAC ~6-8 days; without DAC (mod GRF 1-29) ~30 min, subcutaneous | Verified |
| LanreotideSomatuline Depot · Lanreotide acetate | Growth Hormone | ~23-30 days, extended-release subcutaneous | Verified |
| ACE-031ActRIIB-Fc · Ramatercept | Growth Hormone | Not established in a public source | Verified |
| AdipotideProhibitin-targeting peptide · FTPP | GLP-1 / Metabolic | Not established in a public source | Verified |
| AnamorelinONO-7643 · RC-1291 | Growth Hormone | Not established in a public source | Verified |
| CagriSemaCagrilintide/Semaglutide | GLP-1 / Metabolic | About one week for both components, consistent with the weekly schedule used in trials | Verified |
| CerebrolysinFPF-1070 | Cognitive / Longevity | Not established in a public source, the product being a mixture rather than a single peptide | Verified |
| DanuglipronPF-06882961 | GLP-1 / Metabolic | Not established in a public source | Verified |
| DihexaN-hexanoic-Tyr-Ile-(6) aminohexanoic amide · PNB-0408 | Cognitive / Longevity | Not established in a public source | Verified |
| EcnoglutideXW003 | GLP-1 / Metabolic | Not established in a public source | Verified |
| EpithalonEpitalon · AEDG | Cognitive / Longevity | Not established (no published human PK); expected short for a linear tetrapeptide | Emerging |
| FollistatinFST · Activin-binding protein | Growth Hormone | Not established in a public source | Verified |
| FOXO4-DRIFOXO4 D-retro-inverso peptide | Cognitive / Longevity | Not established in a public source | Verified |
| GDF-11Growth differentiation factor 11 · BMP-11 | Growth Hormone | Not established in a public source | Verified |
| GHK-CuCopper Peptide · Copper tripeptide-1 | Healing / Recovery | Systemic half-life not well characterized; typically studied topically | Verified |
| GHRP-1Growth hormone-releasing peptide-1 | Growth Hormone | Not established in a public source | Verified |
| GIPGlucose-dependent insulinotropic polypeptide · Gastric inhibitory polypeptide | GLP-1 / Metabolic | Minutes in circulation, being rapidly inactivated by DPP-4 | Verified |
| HumaninHN · Mitochondrial-derived peptide | Cognitive / Longevity | Not established in a public source | Verified |
| IGF-1 DESDES(1-3)IGF-1 · des(1-3)IGF-I | Growth Hormone | Not established in a public source | Verified |
| KLOWGHK-Cu + TB-500 + BPC-157 + KPV | Healing / Recovery | Varies by component; see the individual entries | Emerging |
| KPVLysine-Proline-Valine | Healing / Recovery | Not well characterized in humans (preclinical peptide) | Verified |
| LarazotideLarazotide acetate · AT-1001 | Healing / Recovery | Acts locally in the gut; a systemic half-life is not well defined | Verified |
| LivagenLys-Glu-Asp-Ala · KEDA peptide | Cognitive / Longevity | Not established in a public source | Verified |
| LL-37Cathelicidin · CAP-18 | Healing / Recovery | Short in plasma; no human PK published | Verified |
| Maridebart CafraglutideMariTide · AMG 133 | GLP-1 / Metabolic | Long enough to support the once-monthly schedule used in trials | Verified |
| MazdutideIBI362 · LY3305677 | GLP-1 / Metabolic | Weekly administration in registered trials; no human PK in a public label | Verified |
| MGFPEG-MGF · Mechano Growth Factor | Growth Hormone | Not established in a public source | Verified |
| Mod GRF 1-29CJC-1295 without DAC · Modified GRF(1-29) | Growth Hormone | Short, in the range of tens of minutes, and far shorter than the DAC version | Verified |
| N-Acetyl SelankN-Acetyl Selank Amidate · NA-Selank | Cognitive / Longevity | Not established in a public source | Verified |
| N-Acetyl SemaxN-Acetyl Semax Amidate · NA-Semax | Cognitive / Longevity | Not established in a public source | Verified |
| NoopeptOmberacetam · GVS-111 | Cognitive / Longevity | Not established in a public source | Verified |
| PemvidutideALT-801 | GLP-1 / Metabolic | Not established in a public source | Verified |
| PetrelintideZP8396 | GLP-1 / Metabolic | Not established in a public source | Verified |
| PinealonGlu-Asp-Arg · EDR peptide | Cognitive / Longevity | Not established in a public source | Verified |
| Selank | Cognitive / Longevity | A few minutes in plasma (rapidly degraded); intranasal or IV | Verified |
| SLU-PP-332Pan-ERR agonist | Cognitive / Longevity | Not established in a public source | Verified |
| SpadinSortilin propeptide fragment | Cognitive / Longevity | Not established in a public source | Verified |
| TabimorelinNN703 · NNC 26-0703 | Growth Hormone | Not established in a public source | Verified |
| TB-500Thymosin Beta-4 fragment · TB4 | Healing / Recovery | Reported in hours; precise human PK sparse, subcutaneous | Verified |
| TeriparatideForteo · PTH 1-34 | Healing / Recovery | Not stated in the cited label | Verified |
| TesofensineNS2330 | GLP-1 / Metabolic | Long, multi-day reported in clinical studies; not established in a public label | Verified |
| ThymalinThymus polypeptide fraction | Healing / Recovery | Not established in a public source | Verified |
| ThymogenAlpha-glutamyl-tryptophan · Glu-Trp | Healing / Recovery | Not established in a public source | Verified |
| ThymopoietinTMPO · Thymopentin parent peptide | Healing / Recovery | Not established in a public source | Verified |
| Thymosin Beta-10TMSB10 · Tbeta10 | Healing / Recovery | Not established in a public source | Verified |
| Thymosin Beta-4TB4 · Tbeta4 | Healing / Recovery | Short in plasma; no human PK published | Verified |
| ThymulinZinc thymulin · Facteur thymique serique | Healing / Recovery | Not established in a public source | Verified |
| VilonLys-Glu · KE peptide | Cognitive / Longevity | Not established in a public source | Verified |
| VIPVasoactive Intestinal Peptide | Healing / Recovery | Very short, on the order of minutes in plasma | Verified |
Half-life is an educational pharmacology figure drawn from public sources. It describes how long a compound persists, not a schedule, a frequency, or a dosing instruction. Values marked emerging are not corroborated by an authoritative public source.
What half-life describes, and what it does not
Half-life is a property of the molecule and the body, measured in controlled studies. A short half-life means the compound clears quickly; a long one means it lingers. It is a useful way to understand how different compounds behave, and a poor way to invent a plan. Half-life is not a frequency, an interval, or an amount, and nothing on this page should be read as one.
Why the numbers vary so much
Small linear peptides are often degraded by enzymes within minutes. Engineering changes that. Attaching a fatty-acid chain or a group that binds albumin, or adding a stabilizing modification, can stretch a half-life from minutes to days. That is why two compounds in the same class can sit at opposite ends of the table. Where a figure is not established in humans, the reference column marks it as emerging rather than implying a precision that does not exist.
Read the full profile
Each compound name links to its full reference page: identity, mechanism class, storage and handling, and the public sources behind it. Start from the compound library to search or filter the full set.
94 compounds. Educational reference only, compiled from public sources. Not medical advice, diagnosis, treatment, or a dosing recommendation, and not a recommendation to use any compound. Many compounds listed are research materials not approved for human use. Consult a qualified professional.